Axonis Therapeutics

Novel small molecule therapeutics for axon regeneration and tissue reactivation.

Axonis Therapeutics is developing medicines for neuron restoration and neuromodulation. Therapies are aimed at enabling neural tissue to resist degeneration, restore healthy electrical balance, and promote neural regeneration. Successful pre-clinical POC studies have been completed, and a clinical trial is planned for 2024 / 25.


How they’re delivering breakthroughs

  • Next generation KCC2 potentiator to restore healthy electrical balance
  • KCC2 potentiation to reactivate spare neuronal tissue after injury
  • Small molecule therapeutics to silence degenerative signals

How they’re making a difference

  • Clinical trial planned for end of 2024 / 2025
  • Broad disease areas including traumatic injuries to the nervous system, neurodegenerative diseases, epilepsy and pain

The people behind the innovation

Joanna Stanicka, PhD
Chief Executive Officer, President & Founder

Learn more about Axonis

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.